Cargando…
The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
BACKGROUND: Tumour cells may persist at the operative site after seemingly adequate surgery. Radiotherapy is often given in an attempt to prevent repopulation, but this modality cannot be relied upon to prevent locoregional recurrence. An alternative strategy is to take advantage of the requirement...
Autores principales: | Gaballah, K, Oakley, R, Hills, A, Ryan, A, Partridge, M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720249/ https://www.ncbi.nlm.nih.gov/pubmed/19623179 http://dx.doi.org/10.1038/sj.bjc.6605092 |
Ejemplares similares
-
Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006) -
Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014) -
Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007) -
Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008) -
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)